グリア細胞株由来神経栄養因子治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0436
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Glial Cell Line Derived Neurotrophic Factor – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Glial Cell Line Derived Neurotrophic Factor – Pipeline Review, H2 2019′; Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.

The report ‘Glial Cell Line Derived Neurotrophic Factor – Pipeline Review, H2 2019′ outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 8 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Neuropathic Pain (Neuralgia), Glaucoma, Ischemic Stroke, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Peripheral Nerve Injury and Retinal Degeneration.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Overview
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Companies Involved in Therapeutics Development
Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Junaxo Inc
Kai Nuo Bio Sci Co Ltd
Kolon Life Science Inc
Lauren Sciences LLC
Neuroptika Inc
Stem Cell Medicine Ltd
Treeway BV
UniQure NV
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Drug Profiles
AMT-090 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Neurodegenerative Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate GDNF for Brain Ischemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate GDNF for Parkinson’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-812 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-2031 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRO-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate GDNF for Parkinson’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smilagenin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Dormant Products
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Product Development Milestones
Featured News & Press Releases
Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial
Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain
Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment
Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
Feb 18, 2013: Phytopharm Announces Results From Parkinson’s Disease Clinical Trial Of Cogane
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease
Apr 18, 2012: Phytopharm’s Confirmatory Data Supports Effectiveness Of Phytopharm’s Cogane In Amyotrophic Lateral Sclerosis
Jan 16, 2012: Phytopharm’s Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm’s Cogane For Treatment Of Amyotrophic Lateral Sclerosis
Jul 28, 2011: Phytopharm’s Cogane Receives FDA Orphan Drug Status
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Copernicus Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Junaxo Inc, H2 2019
Pipeline by Kai Nuo Bio Sci Co Ltd, H2 2019
Pipeline by Kolon Life Science Inc, H2 2019
Pipeline by Lauren Sciences LLC, H2 2019
Pipeline by Neuroptika Inc, H2 2019
Pipeline by Stem Cell Medicine Ltd, H2 2019
Pipeline by Treeway BV, H2 2019
Pipeline by UniQure NV, H2 2019
Dormant Projects, H2 2019

【掲載企業】

Copernicus Therapeutics Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Junaxo Inc
Kai Nuo Bio Sci Co Ltd
Kolon Life Science Inc
Lauren Sciences LLC
Neuroptika Inc
Stem Cell Medicine Ltd
Treeway BV
UniQure NV

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[グリア細胞株由来神経栄養因子治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆